Vir Biotechnology, Inc. - Company Research Report
Company Overview
Name:
Vir Biotechnology, Inc.
Mission of the Company:
Vir leverages the immense potential of the immune system to address critical unmet medical needs and improve patient outcomes.
Founding Details:
- No information is available regarding the year of founding or the founders of the company.
Key People:
- Chief Executive Officer and Director: Marianne De Backer, M.Sc., Ph.D., MBA
- Executive Vice President and Chief Business Officer: Jeff Calcagno, M.D.
- Executive Vice President, General Counsel and Corporate Secretary: Vanina de Verneuil, J.D.
- Executive Vice President, Therapeutic Area Head Oncology: Mika Kakefuda Derynck, M.D.
- Executive Vice President and Chief Medical Officer: Mark Eisner, M.D., M.P.H.
- Executive Vice President, Chief Human Resources Officer: Jenny Gumm, Ed.D., MBA
- Executive Vice President and Chief Technology Officer: Aine Hanly, Ph.D.
- Executive Vice President and Chief Financial Officer: Jason O’Byrne, MBA
- Executive Vice President and Chief Scientific Officer: Jennifer Eileen Towne, Ph.D.
- Senior Vice President and Senior Research Fellow: Antonio Lanzavecchia, M.D.
- Executive Vice President and Senior Research Fellow: Amalio Telenti, M.D, Ph.D.
Headquarters:
1800 Owens Street, Suite 900, San Francisco, CA 94158
Number of Employees:
- No information is available.
Revenue:
- No information is available.
Known For:
Vir Biotechnology, Inc. is known for discovering, engineering, and developing antibody-based medicines, especially for significant health challenges such as COVID-19 and Ebola.
Products
Product Offerings:
Vir Biotechnology focuses on developing medicines for infectious diseases and oncology through novel platforms.
High-Level Product Descriptions:
1. Next-Generation Antibody Platform:
- Utilizes proprietary discovery and protein engineering techniques for creating monoclonal antibodies.
- Known for cross-neutralization of SARS-CoV-2 and effective Ebola virus infection treatment.
2. PRO-XTENTM Protease-Releasable Masking Technology:
- Allows drug candidates to activate only where needed, reducing damage to healthy cells.
- Ensures prolonged presence of drugs in the bloodstream for effective delivery to action sites.
Key Features:
- Antibody Platform:
- Employs AI (dAIsyTM) for enhanced selectivity and potency optimization.
- PRO-XTEN Technology:
- Protects candidates from body clearance mechanisms, allowing extended action and efficacy.
Recent Developments
Recent Developments and Collaborations:
- Vir is actively developing multiple types of clinical-stage and preclinical candidates for diseases with significant unmet needs.
- Collaborations are ongoing with institutions like Alnylam, GSK, and the Bill & Melinda Gates Foundation for varied treatments and advancements.
New Products Launched:
- Chronic Hepatitis Delta (CHD):
- Ongoing Phase 2 trials with tobevibart and elebsiran for suppressive therapy solutions.
- Chronic Hepatitis B:
- Exploring combination treatments for functional cures.
- Oncology:
- Advancing investigational assets targeting HER2, EGFR, and PSMA with PRO-XTEN technology for cancer treatment.
- COVID-19:
- Developing next-generation mAb, VIR-7229, supported by BARDA, demonstrating potency against broad COVID-19 variants.
- HIV Cure:
- Pursuing a potential HIV cure leveraging broadly neutralizing antibodies.
New Features Added:
- AI and machine learning are increasingly incorporated across platforms to boost performance, efficacy, and selectivity of treatments.
Partnerships:
- Extended collaborations with entities like Alnylam, GSK, Bill & Melinda Gates Foundation, and federal agencies such as BARDA for research and development in various critical disease therapeutic areas.
This detailed report outlines the essential facets of Vir Biotechnology, Inc., spotlighting their endeavors, key developments, executive leadership, and innovative product platforms.
